## CONTENTS

### NOTE TO THE READER ............................................. 5

### LIST OF PARTICIPANTS .............................................. 7

### PREAMBLE

- Background .................................................................. 11
- Objective and Scope .................................................. 11
- Selection of Topics for Monographs ............................... 12
- Data for Monographs .................................................. 13
- The Working Group .................................................... 13
- Working Procedures .................................................... 14
- Exposure Data ........................................................... 14
- Biological Data Relevant to the Evaluation of Carcinogenicity to Humans ........................................... 16
- Evidence for Carcinogenicity in Experimental Animals .......... 17
- Other Relevant Data in Experimental Systems and in Humans ..................................................... 19
- Evidence for Carcinogenicity in Humans .......................... 21
- Summary of Data Reported ......................................... 24
- Evaluation .................................................................. 25
- References .................................................................. 29

### GENERAL REMARKS ............................................... 33

### THE MONOGRAPHS

#### Antineoplastic and immunosuppressive agents

<table>
<thead>
<tr>
<th>Antineoplastic and immunosuppressive agents</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Azacitidine</td>
<td>47</td>
</tr>
<tr>
<td>Chlorozotocin</td>
<td>65</td>
</tr>
<tr>
<td>Ciclosporin</td>
<td>77</td>
</tr>
<tr>
<td>Prednimustine</td>
<td>115</td>
</tr>
<tr>
<td>Thiotepa</td>
<td>123</td>
</tr>
<tr>
<td>Trichlormethine (Trimustine hydrochloride)</td>
<td>143</td>
</tr>
</tbody>
</table>
CONTENTS

Antimicrobial agents

Ampicillin ................................................................. 153
Chloramphenicol .................................................... 169
Nitrofural (Nitrofurazone) ................................. 195
Nitrofurantoin ....................................................... 211

Other drugs

Cimetidine ................................................................. 235
Dantron (Chrysazin; 1,8-Dihydroxyanthraquinone) .................... 265
Furosemide (Frusemide) ............................................ 277
Hydrochlorothiazide .................................................. 293
Paracetamol (Acetaminophen) ..................................... 307

SUMMARY OF FINAL EVALUATIONS ........................................... 333

APPENDIX 1. SUMMARY TABLE OF GENETIC AND RELATED EFFECTS ............................................... 335

APPENDIX 2. ACTIVITY PROFILES FOR GENETIC AND RELATED EFFECTS ........................................ 337

SUPPLEMENTARY CORRIGENDA TO VOLUMES 1-49 ..................... 385

CUMULATIVE INDEX TO THE MONOGRAPHS SERIES ................... 387
NOTE TO THE READER

The term 'carcinogenic risk' in the IARC Monographs series is taken to mean the probability that exposure to an agent will lead to cancer in humans.

Inclusion of an agent in the Monographs does not imply that it is a carcinogen, only that the published data have been examined. Equally, the fact that an agent has not yet been evaluated in a monograph does not mean that it is not carcinogenic.

The evaluations of carcinogenic risk are made by international working groups of independent scientists and are qualitative in nature. No recommendation is given for regulation or legislation.

Anyone who is aware of published data that may alter the evaluation of the carcinogenic risk of an agent to humans is encouraged to make this information available to the Unit of Carcinogen Identification and Evaluation, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France, in order that the agent may be considered for re-evaluation by a future Working Group.

Although every effort is made to prepare the monographs as accurately as possible, mistakes may occur. Readers are requested to communicate any errors to the Unit of Carcinogen Identification and Evaluation, so that corrections can be reported in future volumes.